Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314887 | 1.00 | LTA4H (0.68) | LTA4HFFAR1ALOX5APCASP3CHRNB1 | |
| SCHEMBL4316703 | 0.97 | LTA4H (0.73) | LTA4HFFAR1ALOX5APCASP3 | |
| SCHEMBL4316696 | 0.97 | LTA4H (0.73) | LTA4HFFAR1ALOX5APCASP3 | |
| SCHEMBL4320294 | 0.85 | LTA4H (0.75) | LTA4HFFAR1 | |
| SCHEMBL4320300 | 0.85 | LTA4H (0.75) | LTA4HFFAR1 | |
| SCHEMBL13809008 | 0.84 | LTA4H (0.93) | LTA4HFFAR1 | |
| SCHEMBL990496 | 0.84 | LTA4H (0.58) | LTA4HFFAR1ALOX5AP | |
| SCHEMBL4319104 | 0.84 | LTA4H (0.58) | LTA4HFFAR1ALOX5AP | |
| SCHEMBL4324159 | 0.84 | LTA4H (0.58) | LTA4HFFAR1ALOX5AP | |
| Hydrochloric Acid SCHEMBL4319529 | 0.83 | LTA4H (0.91) | LTA4HFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926708-B1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2014-06-18 | — | — | EP | disclosed |
| US-8598359-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2013-12-03 | — | — | US | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| US-7402684-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENECTICS EHF. (IS) | 2008-07-22 | — | — | US | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885ALOX5AP 21/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885ALOX5AP 21/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885ALOX5AP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.